This new screening compound set belongs to our dedicated Coronavirus Screening Libraries, intended for development of innovative and specific antiviral therapeutics towards COVID-19. 1,700 potential inhibitors of the SARS CoV-2 papain-like protease (PLpro) were selected by docking-based virtual screening from the Life Chemicals HTS Compound Collection.

Our Pre-plated Focused Libraries are aimed to provide convenient starting kits for hit identification in the HTS and HCS drug discovery projects. The compound sets comprise novel drug-like screening compounds synthesized in-house. Several formatting options are available.

The new STING Targeted Library comprises potential agonists of the cellular double-stranded DNA sensor STING. It was created by docking-based virtual screening, resulting in 1,600 drug-like compounds (Ro5-compliant, reactive and toxic groups removed). The docking score value is available for each compound in the compound structure file provided on requests.

Antiviral Libraries were designed with 2D similarity or a combination of ligand-based structure-based approaches and aim high throughput screening (HTS) and high content screening (HCS) projects. Over 13,700 drug-like screening compounds with potential antiviral activity against various virus species and antiviral molecular targets were selected.

Exclusive non-overlapping Pre-plated Diversity Sets are composed of 5,000, 10,000, 15,000, and 20,000 screening compounds (in total, 50,000 novel structurally-diverse molecules) with optimal physico-chemical properties, selected by dissimilarity search with the average Tanimoto threshold of 80%. They are ideal starting kit for phenotypic and target-based HTS.

Life Chemicals efforts to contribute to fighting the COVID-19 resulted in a number of compound libraries, including those specifically focused on cysteine: Cysteine Protease Library (3,700 screening compounds), Cysteine Focused Covalent Inhibitor Library (2,200 potential covalent modifiers), Cysteine Focused Covalent Inhibitor Fragments (1,200 fragments), 2019-nCoV Main Protease Targeted Library (2,300 potential inhibitors).

To facilitate phenotypic drug discovery screening, Life Chemicals has designed two dedicated Phenotypic Screening Libraries: ChemDiversity (7,500 drug-like screening compounds) and BioDiversity (11,000 bioactive molecules and their analogs, together with natural product-related compounds). The Libraries are characterized by high chemical and biological diversity and optimal physicochemical properties.

Life Chemicals has developed its RNA Screening Library of over 3,300 drug-like compounds with predicted RNA-binding activity as an excellent starting point for post-transcriptional gene regulation, antibacterial, and antiviral drug discovery research. It has been designed with two ligand-based approaches: 2D Similarity Search and Bayesian Modeling.